Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim Pharma GmbH & Co. KG

CNS Diseases Research
Birkendorfer Strasse 65
88397 Biberach

Dr. Bernd Sommer

Boehringer Ingelheim International GmbH
Global Head CNS Diseases Research

Phone: +49 7351 54 8265
Fax: +49 7351 54 2171

Send E-Mail
Dr. Gwenaelle Fillon

Principal Translational medicine & Biomarker Expert

Phone: +49 7351 54 142165

Send E-Mail
Prof. Dr. Bastian Hengerer

Director CNS Diseases Research

Phone: +49 7351 54 4742

Send E-Mail
Tatiana Peleh

PhD Student

Phone: +49 7351 54 187441

Send E-Mail
Dr. Dr. Jana Podhorna

Senior Clinical Program Leader

Phone: +49 6132 77 142124

Send E-Mail

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.

Boehringer Ingelheim’s approach in CNS focuses on research to address unanswered challenges and needs in this area. With symptom led research we are investigating the underlying neurobiology of the brain across mental disorders such as schizophrenia, Alzheimer’s disease and depression.

We are optimistic that our symptom led approach, through better understanding of brain circuitry, will lead to the development of effective treatments that can be applied across a range of mental illness.

To complement our own innovation, we partner with academic and clinical experts, companies and research organisations at the forefront of neuroscience and psychiatry. One latest example is our collaboration with the Californian pharmaceutical company Arena. We are keen to explore opportunities to broaden research potential with the wider research community.

Follow us on LinkedIn or Twitter:
LinkedIn Twitter